Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.22) per share for the year, down from their prior estimate of ($3.06). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($4.76) EPS and FY2028 earnings at $1.81 EPS.

Several other equities research analysts have also issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Finally, The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $62.00 to $82.00 in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $84.29.

MoonLake Immunotherapeutics Stock Down 1.9 %

NASDAQ:MLTX opened at $43.23 on Monday. MoonLake Immunotherapeutics has a twelve month low of $37.55 and a twelve month high of $64.98. The stock has a market cap of $2.76 billion, a P/E ratio of -33.51 and a beta of 1.28. The business’s 50-day moving average price is $49.47 and its two-hundred day moving average price is $49.07.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. FMR LLC lifted its holdings in MoonLake Immunotherapeutics by 35.8% in the 3rd quarter. FMR LLC now owns 4,950,224 shares of the company’s stock worth $249,590,000 after buying an additional 1,306,215 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of MoonLake Immunotherapeutics by 4.4% during the third quarter. Westfield Capital Management Co. LP now owns 1,167,358 shares of the company’s stock valued at $58,858,000 after acquiring an additional 49,733 shares in the last quarter. Fred Alger Management LLC boosted its holdings in MoonLake Immunotherapeutics by 1.1% in the third quarter. Fred Alger Management LLC now owns 666,574 shares of the company’s stock valued at $33,609,000 after acquiring an additional 7,545 shares in the last quarter. Victory Capital Management Inc. increased its position in MoonLake Immunotherapeutics by 24.7% during the 3rd quarter. Victory Capital Management Inc. now owns 217,839 shares of the company’s stock valued at $10,983,000 after purchasing an additional 43,157 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in MoonLake Immunotherapeutics by 3.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 118,126 shares of the company’s stock worth $5,956,000 after purchasing an additional 3,892 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.